Asthma Management Guidelines

Core Components of Asthma Management

The American Academy of Allergy, Asthma, and Immunology recommends a comprehensive approach to asthma management, including medications, patient education, environmental control measures, and management of comorbidities 1
The National Asthma Education and Prevention Program suggests that treatment goals include symptom control, restoration of normal lung function, reduction of exacerbation risk, and minimizing medication side effects 2
Regular monitoring of asthma control is necessary to adjust therapy appropriately, as recommended by the American College of Allergy, Asthma, and Immunology 1

For patients with mild persistent asthma, the American Thoracic Society recommends low-dose inhaled corticosteroid (ICS) as the preferred controller medication 1
For patients with moderate persistent asthma, the European Respiratory Society suggests medium-dose ICS monotherapy as an alternative option 1
For patients with severe persistent asthma, the American College of Chest Physicians recommends medium-dose ICS plus long-acting β2-agonist (LABA) combination therapy 1

The British Thoracic Society recommends assessing severity using objective measures, including ability to speak in sentences, respiratory rate, heart rate, and peak expiratory flow (PEF) 3
For mild exacerbations, the National Institute for Health and Care Excellence suggests nebulized salbutamol 5mg or terbutaline 10mg, and prednisolone 30-60mg if PEF remains 50-75% predicted after bronchodilator 3
For severe exacerbations, the American Thoracic Society recommends oxygen 40-60% if available, nebulized salbutamol 5mg or terbutaline 10mg with oxygen as driving gas, and prednisolone 30-60mg or IV hydrocortisone 200mg 4

The American Academy of Allergy, Asthma, and Immunology recommends that patients understand the difference between "relievers" (bronchodilators) and "preventers" (anti-inflammatory medications) 5
The National Asthma Education and Prevention Program suggests that self-management plans should include regular monitoring of symptoms and peak flow, pre-arranged action steps based on symptoms/peak flow, written guidance for medication adjustments, and clear instructions for when to seek urgent medical attention 5

The American Academy of Pediatrics recommends considering daily long-term controller therapy for young children with two or more wheezing episodes in the past year lasting >1 day, or risk factors such as parental asthma history or physician-diagnosed atopic dermatitis 1
The European Respiratory Society suggests using the lowest effective dose of ICS to minimize potential side effects in children, and monitoring response closely and adjusting treatment accordingly 5

The American College of Allergy, Asthma, and Immunology recommends avoiding underestimation of the severity of exacerbations, overreliance on bronchodilators without anti-inflammatory treatment, delayed administration of systemic corticosteroids during severe exacerbations, and sedation in acute asthma 2
The National Institute for Health and Care Excellence suggests avoiding failure to provide patients with written action plans for self-management 5

The American Thoracic Society recommends follow-up within 24-48 hours after acute exacerbations, and regular review of inhaler technique, adherence, and symptom control 2
The European Respiratory Society suggests considering step-down of therapy when asthma has been stable for at least 3 months, and ensuring that patients are not discharged from hospital until symptoms have stabilized with PEF >75% of predicted/personal best 2

Asthma severity should be classified based on current impairment and anticipated risk, which includes daytime symptoms, nighttime awakenings, frequency of short-acting beta agonist use for symptom relief, and interference with normal activities 6
Objective measures such as forced expiratory volume in one second (FEV1) or peak expiratory flow (PEF) should be used to assess severity, with values ≥80% of predicted or personal best indicating well-controlled asthma 6
Self-monitoring is crucial for effective asthma management, with either symptom monitoring or peak flow monitoring providing similar benefits 6

For moderate persistent asthma, alternative treatment options include low-dose inhaled corticosteroid (ICS) plus long-acting beta agonist (LABA) 6
For moderate-to-severe persistent asthma, medium-dose ICS plus LABA is the preferred treatment 6
Alternative options for moderate-to-severe persistent asthma include medium-dose ICS plus leukotriene receptor antagonist, theophylline, or zileuton 6
For severe persistent asthma, high-dose ICS plus LABA with consideration of omalizumab for patients with allergies 6
Addition of oral corticosteroids may be necessary for step 6 of asthma treatment 6